[
  {
    "ts": null,
    "headline": "OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results",
    "summary": "Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Re",
    "url": "https://finnhub.io/api/news?id=58f7a0e9749c3d0deeb92ac8011238d8a0bbdcd5945bfb34a9f16a7988848f88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761768300,
      "headline": "OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results",
      "id": 137260400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Re",
      "url": "https://finnhub.io/api/news?id=58f7a0e9749c3d0deeb92ac8011238d8a0bbdcd5945bfb34a9f16a7988848f88"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?",
    "summary": "The  7% rally over the past month has been outdone only by technology stocks.  The last two months alone have seen  Metsera Avidity Biosciences  Merus,  89bio  and Akera Therapeutics all bought out.  The stock, which many considered dead money at best since last summer, is suddenly finding favor with investors.",
    "url": "https://finnhub.io/api/news?id=77d8261aa81a71d90aa172b2f2b245eb20d86799c34b43dab07289356ace3a04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761754260,
      "headline": "Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?",
      "id": 137258535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The  7% rally over the past month has been outdone only by technology stocks.  The last two months alone have seen  Metsera Avidity Biosciences  Merus,  89bio  and Akera Therapeutics all bought out.  The stock, which many considered dead money at best since last summer, is suddenly finding favor with investors.",
      "url": "https://finnhub.io/api/news?id=77d8261aa81a71d90aa172b2f2b245eb20d86799c34b43dab07289356ace3a04"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback",
    "summary": "Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click for my REGN update.",
    "url": "https://finnhub.io/api/news?id=96d3b63472bc60ae4210f7d007c34adb6434a29456e6e3582744db2527d9a86b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761742827,
      "headline": "Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback",
      "id": 137252892,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/931159582/image_931159582.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click for my REGN update.",
      "url": "https://finnhub.io/api/news?id=96d3b63472bc60ae4210f7d007c34adb6434a29456e6e3582744db2527d9a86b"
    }
  },
  {
    "ts": null,
    "headline": "FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes",
    "summary": "Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.",
    "url": "https://finnhub.io/api/news?id=71ac1db5bd563b8b731a507b839d70ffff0bb1e037bff8af1eb05185bf3b9f5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761742148,
      "headline": "FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes",
      "id": 137248212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.",
      "url": "https://finnhub.io/api/news?id=71ac1db5bd563b8b731a507b839d70ffff0bb1e037bff8af1eb05185bf3b9f5a"
    }
  },
  {
    "ts": null,
    "headline": "Market Starting To Embrace The 'New' Regeneron",
    "summary": "Regeneron Pharmaceuticals, Inc. beat Q3 forecasts. Discover how shifts beyond Eylea and Dupixent profits drive growth potential in 2026. Click for my REGN update.",
    "url": "https://finnhub.io/api/news?id=eadfc10230dcf173a21ec7e05a0ee325d7733364237ed9cc1b2770d0aa23a7d6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761739265,
      "headline": "Market Starting To Embrace The 'New' Regeneron",
      "id": 137249876,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/943660194/image_943660194.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. beat Q3 forecasts. Discover how shifts beyond Eylea and Dupixent profits drive growth potential in 2026. Click for my REGN update.",
      "url": "https://finnhub.io/api/news?id=eadfc10230dcf173a21ec7e05a0ee325d7733364237ed9cc1b2770d0aa23a7d6"
    }
  },
  {
    "ts": null,
    "headline": "OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications",
    "summary": "Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multispecific antibodies for several therapeutic indications of m",
    "url": "https://finnhub.io/api/news?id=459ca0abf6913fadac94f49db1a67eda841a7fca489f1492115558b257c051fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761739200,
      "headline": "OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications",
      "id": 137248213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multispecific antibodies for several therapeutic indications of m",
      "url": "https://finnhub.io/api/news?id=459ca0abf6913fadac94f49db1a67eda841a7fca489f1492115558b257c051fd"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Futures Rise as Fed Rate Cut Decision Looms",
    "summary": "The Morning Bull - US Market Morning Update Wednesday, Oct, 29 2025 US stock futures are narrowly mixed this morning as investors brace for a widely anticipated interest rate cut from the Federal Reserve. Attention is turning to what Chair Jerome Powell signals about the path ahead. Uncertainty around delayed economic data and stubbornly steady Treasury yields is keeping the mood cautious, prompting many investors to weigh how much easier borrowing costs could boost sentiment in the face of...",
    "url": "https://finnhub.io/api/news?id=9df7306e08439d1cb0b23ca8b3d21d08b0c9a358b4faf63bfbc50e8b4449b4cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761732529,
      "headline": "S&P 500 Futures Rise as Fed Rate Cut Decision Looms",
      "id": 137248152,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The Morning Bull - US Market Morning Update Wednesday, Oct, 29 2025 US stock futures are narrowly mixed this morning as investors brace for a widely anticipated interest rate cut from the Federal Reserve. Attention is turning to what Chair Jerome Powell signals about the path ahead. Uncertainty around delayed economic data and stubbornly steady Treasury yields is keeping the mood cautious, prompting many investors to weigh how much easier borrowing costs could boost sentiment in the face of...",
      "url": "https://finnhub.io/api/news?id=9df7306e08439d1cb0b23ca8b3d21d08b0c9a358b4faf63bfbc50e8b4449b4cb"
    }
  },
  {
    "ts": null,
    "headline": "REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was 22.7% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=834f20c3b0f254cb5ba6b14a046ba1d5d7bdf07cb8c3d05d6d49eefc4d0620fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761715964,
      "headline": "REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage",
      "id": 137248215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was 22.7% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=834f20c3b0f254cb5ba6b14a046ba1d5d7bdf07cb8c3d05d6d49eefc4d0620fd"
    }
  },
  {
    "ts": null,
    "headline": "Market Wrap: Top Stock Movers- PayPal, Nokia, and Wayfair",
    "summary": "Market data as of 4pm ET October 28, 2025 The market closed with yet another record win, once again credited to the increasing investments from companies well-versed in artificial intelligence. The S&P 500 closed 0.2% higher, maintaining its third consecutive day of record gains.The ...",
    "url": "https://finnhub.io/api/news?id=d93d512b2e9cf68317663ba5e92ff32062632c9d3259daff7fd558be032b06f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761710580,
      "headline": "Market Wrap: Top Stock Movers- PayPal, Nokia, and Wayfair",
      "id": 137243098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Market data as of 4pm ET October 28, 2025 The market closed with yet another record win, once again credited to the increasing investments from companies well-versed in artificial intelligence. The S&P 500 closed 0.2% higher, maintaining its third consecutive day of record gains.The ...",
      "url": "https://finnhub.io/api/news?id=d93d512b2e9cf68317663ba5e92ff32062632c9d3259daff7fd558be032b06f5"
    }
  }
]